RNAZTranscode Therapeutics, Inc.

Nasdaq transcodetherapeutics.com


$ 0.26 $ -0.01 (-3.18 %)    

Monday, 09-Sep-2024 15:27:27 EDT
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 0.25565
$ 0.26
$ 0.24 x 1,800
-- x --
$ 0.25 - $ 0.26
$ 0.22 - $ 128.00
487,443
na
4.41M
$ -65.45
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 04-01-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-31-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-15-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-31-2022 12-31-2021 10-K
12 11-15-2021 09-30-2021 10-Q
13 08-23-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-transcode-therapeutics-maintains-3-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and maintains $3 pri...

 new-research-published-in-oncotarget-shows-inhibition-of-mir-10b-with-mn-anti-mir10b-nanodrug-targets-stem-cell-like-properties-in-metastatic-breast-cancer-reducing-stemness-and-preventing-metastasis-in-mouse-models-when-combined-with-chemotherapy

https://www.eurekalert.org/news-releases/1055915

 hc-wainwright--co-reiterates-buy-on-transcode-therapeutics-maintains-3-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and maintains $3 pri...

 transcode-therapeutics-13g-filing-shows-3i-lp-reported-a-99-stake-in-the-co-as-of-july-23-2024

- SEC Filing

 transcode-therapeutics-files-for-offering-of-up-to-10m-shares-of-common-stock

- SEC Filing

 why-transcode-therapeutics-rnaz-stock-is-down-60

Transcode Therapeutics shares are trading lower by 62% during Tuesday's session. The company announced pricing of its publi...

 reported-earlier-transcode-therapeutics-prices-3m-public-offering-of-10m-common-shares-at-030share

The Company intends to use the net proceeds from the offering primarily for product development activities, including one or mo...

 transcode-therapeutics-has-regained-compliance-with-nasdaqs-continued-listing-requirements

TransCode Therapeutics, Inc. (NASDAQ:RNAZ), (the "Company"), an RNA oncology company committed to more effectively trea...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION